{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T18:57:34Z","timestamp":1772909854466,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["CH\/1996001\/9454"],"award-info":[{"award-number":["CH\/1996001\/9454"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Medical Research Council","doi-asserted-by":"crossref","award":["CTSU MRC Core Funding QQR"],"award-info":[{"award-number":["CTSU MRC Core Funding QQR"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C500\/A16896"],"award-info":[{"award-number":["C500\/A16896"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12882-017-0545-2","type":"journal-article","created":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T09:52:03Z","timestamp":1493632323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection"],"prefix":"10.1186","volume":"18","author":[{"name":"on behalf of the SHARP Collaborative Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7448-9847","authenticated-orcid":false,"given":"C.","family":"Reith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Staplin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. G.","family":"Herrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Emberson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mafham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Cass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. C.","family":"Craig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Baigent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"Landray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,1]]},"reference":[{"issue":"9493","key":"545_CR1","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2005","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267\u201378.","journal-title":"Lancet"},{"issue":"9753","key":"545_CR2","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet"},{"issue":"1","key":"545_CR3","doi-asserted-by":"publisher","first-page":"e29849","DOI":"10.1371\/journal.pone.0029849","volume":"7","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2012","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012;7(1):e29849.","journal-title":"PLoS One"},{"issue":"9607","key":"545_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","volume":"371","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators","year":"2008","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18\u2008686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117\u201325.","journal-title":"Lancet"},{"issue":"9841","key":"545_CR5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2012","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581\u201390.","journal-title":"Lancet"},{"issue":"9889","key":"545_CR6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339\u201352.","journal-title":"Lancet"},{"issue":"14","key":"545_CR7","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"BC Fellstrom","year":"2009","unstructured":"Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395\u2013407.","journal-title":"N Engl J Med"},{"issue":"3","key":"545_CR8","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238\u201348.","journal-title":"N Engl J Med"},{"issue":"9784","key":"545_CR9","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"The SHARP Collaborative Group","year":"2011","unstructured":"The SHARP Collaborative Group. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181\u201392.","journal-title":"Lancet"},{"issue":"5","key":"545_CR10","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ahj.2010.08.012","volume":"160","author":"The SHARP Collaborative Group","year":"2010","unstructured":"The SHARP Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010;160(5):785\u201394. e710.","journal-title":"Am Heart J"},{"issue":"8A","key":"545_CR11","doi-asserted-by":"publisher","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","volume":"97","author":"M Law","year":"2006","unstructured":"Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97(8A):52C\u201360.","journal-title":"Am J Cardiol"},{"issue":"9601","key":"545_CR12","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","volume":"370","author":"J Armitage","year":"2007","unstructured":"Armitage J. The safety of statins in clinical practice. Lancet. 2007;370(9601):1781\u201390.","journal-title":"Lancet"},{"key":"545_CR13","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388: 2532\u201361.","journal-title":"Lancet"},{"issue":"24","key":"545_CR14","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1001\/jama.2011.860","volume":"305","author":"D Preiss","year":"2011","unstructured":"Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556\u201364.","journal-title":"JAMA"},{"issue":"9716","key":"545_CR15","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","volume":"375","author":"N Sattar","year":"2010","unstructured":"Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735\u201342.","journal-title":"Lancet"},{"issue":"6","key":"545_CR16","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMoa061894","volume":"355","author":"The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators","year":"2006","unstructured":"The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549\u201359.","journal-title":"N Engl J Med"},{"key":"545_CR17","doi-asserted-by":"publisher","first-page":"c2197","DOI":"10.1136\/bmj.c2197","volume":"340","author":"J Hippisley-Cox","year":"2010","unstructured":"Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197.","journal-title":"BMJ"},{"issue":"2","key":"545_CR18","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","volume":"56","author":"E Bjornsson","year":"2012","unstructured":"Bjornsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56(2):374\u201380.","journal-title":"J Hepatol"},{"key":"545_CR19","doi-asserted-by":"publisher","first-page":"f880","DOI":"10.1136\/bmj.f880","volume":"346","author":"CR Dormuth","year":"2013","unstructured":"Dormuth CR, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB, Lafrance JP, Levy A, Garg AX, Ernst P, et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ. 2013;346:f880.","journal-title":"BMJ"},{"issue":"7","key":"545_CR20","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1592\/phco.29.7.800","volume":"29","author":"MA Evans","year":"2009","unstructured":"Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy. 2009;29(7):800\u201311.","journal-title":"Pharmacotherapy"},{"issue":"6","key":"545_CR21","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40264-014-0163-x","volume":"37","author":"M Takada","year":"2014","unstructured":"Takada M, Fujimoto M, Yamazaki K, Takamoto M, Hosomi K. Association of statin use with sleep disturbances: data mining of a spontaneous reporting database and a prescription database. Drug Saf. 2014;37(6):421\u201331.","journal-title":"Drug Saf"},{"issue":"11","key":"545_CR22","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1136\/thx.2006.062885","volume":"61","author":"EM Garde van de","year":"2006","unstructured":"van de Garde EM, Hak E, Souverein PC, Hoes AW, van den Bosch JM, Leufkens HG. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax. 2006;61(11):957\u201361.","journal-title":"Thorax"},{"issue":"1","key":"545_CR23","doi-asserted-by":"publisher","first-page":"e52929","DOI":"10.1371\/journal.pone.0052929","volume":"8","author":"AR Khan","year":"2013","unstructured":"Khan AR, Riaz M, Bin Abdulhak AA, Al-Tannir MA, Garbati MA, Erwin PJ, Baddour LM, Tleyjeh IM. The role of statins in prevention and treatment of community acquired pneumonia: a systematic review and meta-analysis. PLoS One. 2013;8(1):e52929.","journal-title":"PLoS One"},{"issue":"5","key":"545_CR24","doi-asserted-by":"publisher","first-page":"976 e971\u2013976","DOI":"10.1016\/j.ahj.2006.02.013","volume":"151","author":"S Atar","year":"2006","unstructured":"Atar S, Cannon CP, Murphy SA, Rosanio S, Uretsky BF, Birnbaum Y. Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial. Am Heart J. 2006;151(5):976 e971\u2013976.","journal-title":"Am Heart J"},{"issue":"16 Pt 2","key":"545_CR25","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1212\/01.wnl.0000286942.14552.51","volume":"70","author":"AD Wahner","year":"2008","unstructured":"Wahner AD, Bronstein JM, Bordelon YM, Ritz B. Statin use and the risk of Parkinson disease. Neurology. 2008;70(16 Pt 2):1418\u201322.","journal-title":"Neurology"},{"issue":"5","key":"545_CR26","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1212\/WNL.0b013e31829d873c","volume":"81","author":"YC Lee","year":"2013","unstructured":"Lee YC, Lin CH, Wu RM, Lin MS, Lin JW, Chang CH, Lai MS. Discontinuation of statin therapy associates with Parkinson disease: a population-based study. Neurology. 2013;81(5):410\u20136.","journal-title":"Neurology"},{"issue":"9222","key":"545_CR27","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1016\/S0140-6736(00)02400-4","volume":"355","author":"KA Chan","year":"2000","unstructured":"Chan KA, Andrade SE, Boles M, Buist DSM, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet. 2000;355(9222):2185\u20138.","journal-title":"Lancet"},{"issue":"16","key":"545_CR28","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1001\/jama.2009.1488","volume":"302","author":"DJ Jager de","year":"2009","unstructured":"de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, Collart F, Finne P, Heaf JG, De Meester J, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA. 2009;302(16):1782\u20139.","journal-title":"JAMA"},{"key":"545_CR29","unstructured":"Inegy tablets; Summary of Product Characteristics. \nhttps:\/\/www.medicines.org.uk\/emc\/medicine\/15657#PRODUCTINFO\n\n. Accessed 11 Apr 2017."},{"issue":"5","key":"545_CR30","doi-asserted-by":"publisher","first-page":"914","DOI":"10.2215\/CJN.10371013","volume":"9","author":"The SHARP Collaborative Group","year":"2014","unstructured":"The SHARP Collaborative Group. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. Clin J Am Soc Nephrol 2014: 9(5) 914\u2013919.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"545_CR31","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jama.2015.1206","volume":"313","author":"J Besseling","year":"2015","unstructured":"Besseling J, Kastelein JJ, Defesche JC, Hutten BA, Hovingh GK. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA. 2015;313(10):1029\u201336.","journal-title":"JAMA"},{"issue":"22","key":"545_CR32","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","volume":"375","author":"BA Ference","year":"2016","unstructured":"Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, Voros S, Giugliano RP, Davey Smith G, Fazio S, et al. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. N Engl J Med. 2016;375(22):2144\u201353.","journal-title":"N Engl J Med"},{"key":"545_CR33","doi-asserted-by":"publisher","unstructured":"Schmidt AF, Swerdlow DI, Holmes MV, Patel RS, Fairhurst-Hunter Z, Lyall DM, Hartwig FP, Horta BL, Hypponen E, Power C, et al. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol. 2017;5(2):97-105. doi:\n10.1016\/S2213-8587(16)30396-5\n\n.","DOI":"10.1016\/S2213-8587(16)30396-5"},{"issue":"13","key":"545_CR34","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/jama.2016.14568","volume":"316","author":"LA Lotta","year":"2016","unstructured":"Lotta LA, Sharp SJ, Burgess S, Perry JR, Stewart ID, Willems SM, Luan J, Ardanaz E, Arriola L, Balkau B, et al. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis. JAMA. 2016;316(13):1383\u201391.","journal-title":"JAMA"},{"key":"545_CR35","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1017\/S0950268898001435","volume":"121","author":"C Iribarren","year":"1998","unstructured":"Iribarren C. Cohort study of serum total cholesterol and in-hospital incidence of infectious diseases. Epidemiol Infect. 1998;121:335\u201347.","journal-title":"Epidemiol Infect"},{"issue":"6","key":"545_CR36","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/ije\/26.6.1191","volume":"26","author":"C Iribarren","year":"1997","unstructured":"Iribarren C, Jacobs Jr DR, Sidney S, Claxton AJ, Gross MD, Sadler M, Blackburn H. Serum total cholesterol and risk of hospitalization, and death from respiratory disease. Int J Epidemiol. 1997;26(6):1191\u2013202.","journal-title":"Int J Epidemiol"},{"issue":"4","key":"545_CR37","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1378\/chest.06-1997","volume":"131","author":"FJ Frost","year":"2007","unstructured":"Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007;131(4):1006\u201312.","journal-title":"Chest"},{"issue":"23","key":"545_CR38","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa1401520","volume":"370","author":"National Heart Lung Blood Institute ARDS Clinical Trials Network","year":"2014","unstructured":"National Heart Lung Blood Institute ARDS Clinical Trials Network. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med. 2014;370(23):2191\u2013200.","journal-title":"N Engl J Med"},{"issue":"23","key":"545_CR39","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1056\/NEJMoa1403086","volume":"370","author":"GJ Criner","year":"2014","unstructured":"Criner GJ, Connett JE, Aaron SD, Albert RK, Bailey WC, Casaburi R, Cooper Jr JA, Curtis JL, Dransfield MT, Han MK, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med. 2014;370(23):2201\u201310.","journal-title":"N Engl J Med"},{"issue":"18","key":"545_CR40","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa1403285","volume":"371","author":"DF McAuley","year":"2014","unstructured":"McAuley DF, Laffey JG, O\u2019Kane CM, Perkins GD, Mullan B, Trinder TJ, Johnston P, Hopkins PA, Johnston AJ, McDowell C, et al. Simvastatin in the acute respiratory distress syndrome. N Engl J Med. 2014;371(18):1695\u2013703.","journal-title":"N Engl J Med"},{"issue":"1","key":"545_CR41","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1046\/j.1523-1755.2001.00487.x","volume":"59","author":"LF Fried","year":"2001","unstructured":"Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59(1):260\u20139.","journal-title":"Kidney Int"},{"issue":"18","key":"545_CR42","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1056\/NEJMoa1507750","volume":"374","author":"Z Zheng","year":"2016","unstructured":"Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q, Du J, Guarguagli S, Hill M, Chen Z, et al. Perioperative Rosuvastatin in Cardiac Surgery. N Engl J Med. 2016;374(18):1744\u201353.","journal-title":"N Engl J Med"},{"issue":"8","key":"545_CR43","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1681\/ASN.2013090965","volume":"25","author":"The SHARP Collaborative Group","year":"2014","unstructured":"The SHARP Collaborative Group. Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol. 2014;25(8):1825\u201333.","journal-title":"J Am Soc Nephrol"},{"issue":"9808","key":"545_CR44","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/S0140-6736(11)61125-2","volume":"378","author":"R Bulbulia","year":"2011","unstructured":"Bulbulia R, Bowman L, Wallendszus K, Parish S, Armitage J, Peto R, Collins R. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5\u00a0years in 20,536 high-risk individuals: a randomised controlled trial. Lancet. 2011;378(9808):2013\u201320.","journal-title":"Lancet"},{"issue":"11","key":"545_CR45","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.115.019014","volume":"133","author":"I Ford","year":"2016","unstructured":"Ford I, Murray H, McCowan C, Packard CJ. Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of west of Scotland coronary prevention study. Circulation. 2016;133(11):1073\u201380.","journal-title":"Circulation"},{"key":"545_CR46","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ahj.2016.01.016","volume":"176","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2016","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration. Protocol for analyses of adverse event data from randomized controlled trials of statin therapy. Am Heart J. 2016;176:63\u20139.","journal-title":"Am Heart J"},{"issue":"3","key":"545_CR47","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","volume":"371","author":"HPS2-THRIVE Collaborative Group","year":"2014","unstructured":"HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203.","journal-title":"N Engl J Med"},{"key":"545_CR48","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397.","journal-title":"N Engl J Med"},{"key":"545_CR49","unstructured":"Merck Sharp and Dohme. IMPROVE-IT Study. Food and Drug Administration Endocrinologic and Metabolic Drug Products Advisory Committee Briefing Document. 2015. \nhttps:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM476506.pdf\n\n. Accessed 30 Mar 2016."}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-017-0545-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T11:20:49Z","timestamp":1526642449000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-017-0545-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["545"],"URL":"https:\/\/doi.org\/10.1186\/s12882-017-0545-2","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,1]]},"article-number":"147"}}